Actively Recruiting
Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II: Texture Analysis and Artificial Intelligence
Led by Central Hospital, Nancy, France · Updated on 2020-07-21
740
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
C
Central Hospital, Nancy, France
Lead Sponsor
L
Lorraine Cancer Institute - ICL
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating new artificial intelligence (AI) techniques to improve the way images are processed and analyzed for patients with musculoskeletal tumors, which include soft tissue and bone tumors. The study focuses on comparing texture parameters from MRI and ultra-high resolution CT scans to distinguish between benign and malignant tumors. Histological analysis is used as the standard to verify these imaging results and better characterize the tumors. The study compares the diagnostic accuracy of texture parameters derived from different MRI sequences and ultra-high resolution CT images. It also assesses the added value of ultra-high resolution CT compared to standard resolution CT. Additionally, the effectiveness and accuracy of AI-based tools for automatic tumor segmentation are being evaluated. The use of trabecular analysis on ultra-high resolution CT images to examine tumor-bone interfaces is also part of the study. Participants suspected of having bone or soft-tissue tumors undergo imaging with MRI and CT scans. Researchers review imaging results and compare them to histological findings to determine tumor benignancy or malignancy within six months. They also assess sarcoma grading up to one year after imaging. This observational study collects data to improve diagnostic methods, with no treatment interventions involved. The study started in June 2020 and will continue until June 2030.
CONDITIONS
Brief Title
Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients suspected to have a bone or soft-tissue tumor referred for imaging for initial tumors characterization and staging
- Age 18 years or older
You will not qualify if you...
- Pregnancy
- Breast feeding patients
- Renal insufficiency
- Contraindications to MRI or CT
- Prior surgery or treatment to the evaluated lesion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 day
Participants undergo MRI and ultra-high resolution CT imaging to characterize musculoskeletal tumors using texture analysis and artificial intelligence tools.
1 to 2 imaging visits
Duration - Up to 1 year
Participants are followed for up to 6 months to 1 year for outcome assessments including lesion benignancy or malignancy and tumor grading.
Assessments performed up to 6 months and 1 year after imaging
Trial Site Locations
Total: 1 location
1
CHU-Nancy
Nancy, Lorraine, France, 54000
Actively Recruiting
Research Team
P
Pedro Gondim Teixieira, PhD
G
Gabriela Hossu, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here